MedPath

Bristol Myers' TYK2 Inhibitor Shows Promise in Phase 3 Psoriatic Arthritis Trials

Bristol Myers Squibb's TYK2 inhibitor has demonstrated success in a pair of Phase 3 clinical trials targeting psoriatic arthritis, marking a significant advancement in the treatment of this condition.

Bristol Myers Squibb has reported positive outcomes from two Phase 3 clinical trials of its TYK2 inhibitor for the treatment of psoriatic arthritis. This development is a significant step forward in the search for effective treatments for this chronic inflammatory disease, which affects millions of people worldwide. The TYK2 inhibitor, by targeting a specific pathway involved in the immune response, offers a novel approach to managing the symptoms and progression of psoriatic arthritis. While the detailed results of these trials have not been disclosed, the success in Phase 3 trials suggests that the TYK2 inhibitor could soon become a valuable new option for patients suffering from this debilitating condition.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Approves Eli Lilly's Omvoh (mirikizumab) for Crohn's Disease and Roche's Susvimo Implant for Diabetic Macular Edema

Eli Lilly's Omvoh (mirikizumab) has received FDA approval for treating moderate to severe Crohn's disease in adults, marking a new option targeting the IL-23 pathway.
Roche's Susvimo implant has been re-approved by the FDA for diabetic macular edema (DME), offering a long-term treatment alternative with reduced injection frequency.

Regor's Obesity Pill Shows Modest Weight Loss in Phase 2a, Advances to New Trial

Regor's obesity treatment has demonstrated modest weight loss results in its Phase 2a trial and is now moving forward into a new clinical trial.

AbbVie Writes Off $3.5B on Cerevel Drug After Phase 2 Failures

AbbVie has decided to write off $3.5 billion invested in a Cerevel drug following unsuccessful Phase 2 clinical trials.

Advancements in Clinical Trials: Cell Therapies for Parkinson's, Protein Degraders for IgAN, High-Dose Wegovy, Schizophrenia Treatment, and Stem Cell Therapy for IVF

BlueRock Therapeutics, a Bayer subsidiary, is advancing its cell therapy for Parkinson's disease directly to a Phase 3 trial, aiming to provide a novel treatment option.
Biohaven is moving its protein degrader for IgA nephropathy (IgAN) into Phase 3 trials after promising early results, addressing a significant unmet need in kidney disease.

Acelyrin's Stock Drops Due to Mixed Phase 2 Data

Acelyrin reports mixed results from Phase 2 trials of a potential treatment for thyroid eye disease, leading to a drop in stock prices.

Sotyktu Meets Primary Endpoints in Phase 3 Psoriatic Arthritis Trials

Bristol Myers Squibb's Sotyktu (deucravacitinib) demonstrated significant efficacy in two Phase 3 trials for active psoriatic arthritis (PsA).
The POETYK PsA-1 and PsA-2 trials met their primary endpoint, showing a greater proportion of Sotyktu-treated patients achieved ACR20 response at Week 16 compared to placebo.

Tirzepatide Achieves Primary and Secondary Endpoints in Phase 3 Trial for Weight Management

Eli Lilly's tirzepatide demonstrated significant weight reduction in a Phase 3 clinical trial, meeting both primary and secondary endpoints.
Participants treated with tirzepatide experienced notable improvements in body weight compared to the placebo group.

Alumis' Oral TYK2 Inhibitor ESK-001 Shows Sustained Efficacy in Psoriasis Phase 2 Extension

Alumis Inc. announced positive 28-week data from the open-label extension of its Phase 2 STRIDE trial of ESK-001 for moderate-to-severe plaque psoriasis.
The data showed that 93% of patients on the 40 mg twice-daily dose achieved PASI 75, demonstrating sustained efficacy over time.

Sanofi Highlights Phase 3 Sarclisa Data in Multiple Myeloma Treatment

Sanofi has recently showcased promising Phase 3 data for its Sarclisa treatment in multiple myeloma, aiming to compete with J&J's Darzalex.

Alder BioPharmaceuticals Announces Positive Eptinezumab Phase 3 Results for Migraine Prevention

Alder BioPharmaceuticals has reported positive top-line results from its Phase 3 PROMISE 1 clinical trial for eptinezumab, a treatment aimed at preventing frequent episodic migraines. The trial met its primary and key secondary endpoints, showing significant reductions in monthly migraine days and a notable proportion of patients experiencing no migraines in any given month over six months.

Reference News

[1]
Bristol Myers' TYK2 inhibitor succeeds in pair of Phase 3 psoriatic arthritis trials
endpts.com · Dec 23, 2024

Endpoints subscribers can request a magic link for password-free login, valid once and expires in 24 hours. Alternativel...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy